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Impaired Renal Function Is Associated With
Echocardiographic Nonresponse and Poor
Prognosis After Cardiac Resynchronization Therapy
Rutger J. Van Bommel, MD, Sjoerd A. Mollema, MD, PHD, C. Jan Willem Borleffs, MD, PHD,
Matteo Bertini, MD, Claudia Ypenburg, MD, PHD, Nina Ajmone Marsan, MD,
Victoria Delgado, MD, PHD, Ernst E. Van Der Wall, MD, PHD, Martin J. Schalij, MD, PHD,
Jeroen J. Bax, MD, PHD
Leiden, the Netherlands
Objectives Aims of this study were to investigate the effect of renal function on left ventricular (LV) reverse remodeling and
long-term outcome after cardiac resynchronization therapy (CRT), and to explore the relation between LV reverse
remodeling and changes in renal function at 6-month follow-up.
Background Renal insufficiency is highly prevalent in heart failure patients, including patients eligible for CRT, and is associ-
ated with poor prognosis.
Methods The study comprised 490 patients undergoing CRT. Response to CRT was defined as a decrease in LV end-systolic
volume 15% at 6-month follow-up. Primary end point during long-term follow-up was all-cause mortality.
Results At baseline, mean estimated glomerular filtration rate (eGFR) was 70  28 ml/min/1.73 m2. At 6-month follow-
up, 263 patients (54%) demonstrated response to CRT. Responders had an eGFR of 74  26 ml/min/1.73 m2
versus 64  28 ml/min/1.73 m2 in nonresponders (p  0.001). During long-term follow-up, patients with an
eGFR 60 ml/min/1.73 m2 had higher mortality than patients with an eGFR of 60 to 90 ml/min/1.73 m2 or an
eGFR 90 ml/min/1.73 m2 (p  0.001). Finally, responders to CRT had preservation of renal function (eGFR
0.6), whereas nonresponders had a slight worsening in renal function (eGFR 4.7, p  0.05).
Conclusions Impaired renal function in CRT candidates is associated with nonresponse during 6-month follow-up. Addition-
ally, patients with impaired renal function have worse long-term survival after CRT. Response to CRT results in
preservation of renal function. (J Am Coll Cardiol 2011;57:549–55) © 2011 by the American College of Cardi-
ology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.06.060C
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tardiac resynchronization therapy (CRT) is a well-
stablished treatment for patients with symptomatic heart
ailure, depressed left ventricular (LV) ejection fraction
LVEF), and a QRS complex 120 ms (1). Several studies
ave demonstrated not only improvement in clinical symp-
oms, exercise capacity, quality of life (QoL), and LV
ystolic function, but also increased survival and lower
ncidence of heart failure–related hospital admissions in
atients treated with CRT as compared with patients
eceiving optimal medical treatment alone (2–4).
rom the Department of Cardiology, Leiden University Medical Center, Leiden, the
etherlands. Prof. Bax received grants from Medtronic, Biotronik, Boston Scientific,
MS Medical Imaging, St. Jude Medical, Edwards Life Sciences, and GE Health-
are. Prof. Schalij received grants from Biotronik, Medtronic, and Boston Scientific.
ohn C. Burnett, Jr., MD, served as Guest Editor for this paper.l
Manuscript received April 12, 2010; revised manuscript received June 1, 2010,
ccepted June 3, 2010.In addition to the above-mentioned beneficial effects of
RT, improvement in LV systolic function in these patients
as recently been linked to a sustained improvement in
ystemic hemodynamics (5,6). One study demonstrated that
atients with significant LV reverse remodeling after CRT
howed an improvement in renal function, and in turn, this
mprovement in renal function resulted in improved survival
fter CRT (6).
Renal failure is common in heart failure patients and is
ssociated with poor long-term prognosis (7–11). Many of
hese heart failure patients are considered candidates for CRT.
he beneficial effect of CRT on systemic hemodynamics
including renal function) can be a possible explanation for the
ncreased survival that is observed in these patients.
Accordingly, aims of the current study were to: 1) investigate
he effect of renal function on LV reverse remodeling and
ong-term outcome after CRT; and 2) explore the relation
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6-month follow-up and changes in
renal function.
Methods
Patient population and proto-
col. Out of a large single-center
registry including all patients re-
ferred for CRT implantation, 490
patients were included who pre-
sented with heart failure symp-
toms according to New York
Heart Association (NYHA) func-
tional class III or IV and had
routinely acquired blood samples
at the time of implantation avail-
able. Patients were included be-
tween 1999 and 2007. All devices
were implanted according to cur-
rent guidelines (1). Before CRT
device implantation, blood sam-
ples were obtained for evaluation
of renal function, and patients
were divided into 3 subgroups
ased on baseline estimated glomerular filtration rate (eGFR).
ll patients underwent extensive evaluation, including assess-
ent of clinical status as well as transthoracic 2-dimensional
2D)-echocardiography before CRT implantation and at
-month follow-up. Medication remained unchanged during
he 6-month follow-up period. Response to CRT was defined
s a reduction 15% in left ventricular end-systolic volume
LVESV) at 6-month follow-up (12,13). Patients who died
ithin the 6-month follow-up period or underwent heart
ransplantation were classified as nonresponders. All-cause
ortality was evaluated during a mean follow-up of 26  21
onths.
The relation between baseline renal function and echo-
ardiographic response at 6-month follow-up, as well as
ong-term prognosis after CRT, was assessed in all patients.
inally, in a subset of 133 patients with routinely acquired
lood samples at 6-month follow-up, the effect of CRT on
enal function was evaluated.
etermination of renal function. Before CRT implanta-
ion (and at 6-month follow up in 133 patients), venous
lood samples were obtained. All blood samples were
nalyzed at the Leiden University Medical Center, the
etherlands. Estimated GFR was calculated using the
tandard formula by Cockcroft and Gault and expressed in
l/min/1.73 m2 (14). Patients were divided into 3 sub-
roups according to the cutoff values proposed by the
ational Kidney Foundation practice guidelines: an eGFR
90 ml/min/1.73 m2 for normal kidney function, an eGFR
0 to 90 ml/min/1.73 m2 for mildly decreased, and an
GFR 60 ml/min/1.73 m2 for moderately to severely
Abbreviations
and Acronyms
2D  2-dimensional
6MWT  6-min walk test
ACE  angiotensin-
converting enzyme
AII  angiotensin II
receptor
CRT  cardiac
resynchronization therapy
eGFR  estimated
glomerular filtration rate
LV  left ventricular
LVEF  left ventricular
ejection fraction
LVEDV  left ventricular
end-diastolic volume
LVESV  left ventricular
end-systolic volume
MR  mitral regurgitation
NYHA  New York Heart
Association
QoL  quality of lifeecreased kidney function (15). cchocardiographic evaluation. All patients underwent
D-echocardiography in the left lateral decubitus position
efore CRT device implantation and at 6-month follow-up.
tudies were performed using a commercially available
chocardiographic system (VIVID 7, General Electric
ingmed Ultrasound, Milwaukee, Wisconsin). Images were
btained using a 3.5 MHz transducer, at a depth of 16 cm
n the parasternal (long- and short-axis) and apical (2- and
-chamber images) views. Standard 2D and color Doppler
ata, triggered to the QRS complex, were saved in cineloop
ormat. A minimum of 3 consecutive beats were recorded
rom each view, and the images were digitally stored for
ffline analysis (EchoPac 7.0.0, General Electric Vingmed
ltrasound). LVESV, left ventricular end-diastolic volume
LVEDV), and LVEF were measured from the apical 2-
nd 4-chamber images, using the modified biplane Simp-
on’s rule (16). Severity of mitral regurgitation (MR) was
raded semiquantitatively from color-flow Doppler images
t the parasternal long-axis and the apical 4-chamber view
nd expressed as the ratio of regurgitant jet area to left atrial
rea (17). Response to CRT was defined as a reduction
15% in LVESV after 6-month follow-up (12,13).
linical evaluation. Clinical status of the patients was
valuated at baseline and at 6-month follow-up. Assessed
arameters included: NYHA functional class, QoL accord-
ng to the Minnesota Living with Heart Failure question-
aire (18) and distance covered in the 6-min walk test
6MWT) (19). Outcome data were collected by chart
eview, device interrogation, and telephone contact. Primary
nd point was death from any cause.
evice implantation. The LV lead was inserted trans-
enously via the subclavian route. A coronary sinus
enogram was obtained using a balloon catheter. Next, the
V pacing lead was inserted through the coronary sinus
ith the help of an 8-F guiding catheter and positioned as
ar as possible in the venous system, preferably in a
postero-) lateral vein. The right atrial and ventricular leads
ere positioned conventionally, and all leads were con-
ected to a dual-chamber biventricular implantable cardiac
evice.
tatistical analysis. Continuous data are presented as
ean  SD, and dichotomous data are presented as
umbers and percentages. Comparison of data between
atient groups was performed using the independent-
amples t test for continuous data. The chi-square test was
sed to compare dichotomous data. Comparison of data
ithin patient groups (at baseline and at 6-month follow-
p) was performed with the paired-samples t test. Compar-
sons between more than 2 patient groups were performed
sing 1-way analysis of variance (ANOVA) with Bonferroni
ost hoc testing. Survival of patients was evaluated with the
aplan-Meier method. The effect of renal function on
urvival was investigated using the Cox proportional hazards
odel, adjusting for age, sex, etiology of heart failure, QRS
uration, NYHA functional class, use of angiotensin-
onverting enzyme (ACE) inhibitors or angiotensin II
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February 1, 2011:549–55 Renal Function in CRTeceptor (AII) blockers, use of diuretics, LV volumes,
VEF, and mitral regurgitation (MR) grade. Variables that
howed a statistically significant effect at the 0.05 level on
event-free) survival in univariable analyses were entered in
he multivariable Cox proportional hazards model, using a
ackward stepwise selection to obtain the final model. At
ach step, the least significant variable was discarded from
he model until all variables in the model reached a p value
elow 0.25. All analyses were performed with SPSS for
indows, version 16.0 (SPSS Inc., Chicago, Illinois). All
tatistical tests were 2-sided. A p value 0.05 was consid-
red statistically significant.
esults
atient characteristics. A total of 490 consecutive patients
ere included. Optimal medical therapy was administered
o all patients when tolerated, as evidenced by 90% usage of
CE-inhibitors or AII-blockers and 86% usage of diuretics.
atients had severely depressed LV function, with a mean
VEF of 24 8%. Mean plasma creatinine level was 115
3 mol/l, and mean estimated creatinine clearance was 70 28
l/min/1.73 m2.
esponse to CRT. In the overall population, improve-
ent in both clinical and echocardiographic parameters at
-month follow-up was observed. Mean NYHA functional
lass declined from 3.1 0.3 to 2.1 0.6 (p 0.001), QoL
mproved from 36  17 to 25  18 (p  0.001), and
MWT increased from 300  106 m to 392  124 m (p 
.001). Furthermore, a decrease in LVEDV from 227  83
l to 198  46 ml (p  0.001), a decrease in LVESV from
72  74 ml to 138  66 ml (p  0.001), and a
onsequential increase in LVEF from 25 8% to 32 10%
p  0.001) were noted. Table 1 provides an overview of
atient characteristics for CRT responders (n  263, 54%)
ersus CRT nonresponders (n  227, 46%). No differences
etween responders and nonresponders existed at baseline
xcept for a more frequently observed ischemic etiology of
eart failure in nonresponders (p  0.001). Furthermore,
onresponders had higher plasma creatinine levels and
ower eGFR (p  0.001 for both) (Table 1).
enal function and response to CRT. To evaluate renal
unction as an indicator for response to CRT, patients were
ivided into 3 subgroups according to the National Kidney
oundation practice guidelines; patients with an eGFR60
l/min/1.73 m2 (n 193), patients with an eGFR 60 to 90
l/min/1.73 m2 (n  204), and patients with an eGFR
90 ml/min/1.73 m2 (n  93). Baseline characteristics of
he 3 subgroups are displayed in Table 2. Patients with
igher eGFR tended to be younger, have a less wide QRS
omplex, use fewer diuretics, and have a better exercise
olerance, higher LVEF, and less MR. Next, response rates
n the 3 subgroups were assessed and are displayed in Figure 1.
ignificantly fewer patients (43%) in the group with mod-
rately to severely decreased kidney function (eGFR 60
l/min/1.73 m2) demonstrated echocardiographic response (o CRT at 6-month follow-up as compared with the 2 other
roups (p  0.001 for eGFR 60 ml/min/1.73 m2 vs.
GFR 60 to 90 ml/min/1.73 m2, and p  0.023 for eGFR
60 ml/min/1.73 m2 vs. eGFR 90 ml/min/1.73 m2). No
ifferences in response rate were observed between the
roup with an eGFR 90 ml/min/1.73 m2 (58% respond-
rs) and the group with an eGFR 60 to 90 ml/min/1.73 m2
62% responders, p  0.609).
enal function and long-term prognosis after CRT. Re-
al function was also investigated in relation to mortality
fter CRT. At the end of the follow-up period (mean: 26 
1 months), 106 patients (22%) had died. Survival between
he 3 patient subgroups (eGFR 60 ml/min/1.73 m2,
GFR 60 to 90 ml/min/1.73 m2, and eGFR 90 ml/min/
.73 m2) was compared using Kaplan-Meier curves. Pa-
ients with an eGFR 60 ml/min/1.73 m2 had a signifi-
antly worse survival as compared with the other 2 groups
atient Characteristicsf R sponders and Nonresponders to CRTTable 1 Pa ient Characteristicsof Responders and Nonresponders to CRT
Variable
Responders
(n  263)
Nonresponders
(n  227) p Value
Age, yrs 65 10 66 11 0.392
Sex, M/F 202/61 190/37 0.070
Ischemic etiology 129 (49%) 164 (72%) <0.001
QRS duration, ms 159 33 154 31 0.130
Systolic blood pressure, mm Hg 111 20 113 22 0.438
Diastolic blood pressure, mm Hg 69 11 70 13 0.716
ACE-inhibitors/AII-blocker 238 (90%) 208 (92%) 0.752
Diuretics 221 (84%) 203 (89%) 0.086
Spironolactone 122 (46%) 118 (52%) 0.239
Beta-blockers 185 (70%) 153 (67%) 0.494
Serum creatinine, mol/l 104 30 127 51 <0.001
eGFR, ml/min/1.73 m2 74 26 64 28 <0.001
NYHA functional class
Baseline 3.1 0.3 3.1 0.3 0.326
Follow-up 1.9 0.6* 2.3 0.7* <0.001
6MWT, m
Baseline 308 99 291 113 0.112
Follow-up 417 108* 358 136* <0.001
QoL score
Baseline 35 16 38 18 0.132
Follow-up 21 16* 29 20* <0.001
LVEDV, ml
Baseline 234 86 219 79 0.055
Follow-up 179 71* 223 75 <0.001
LVESV, ml
Baseline 176 77 167 70 0.181
Follow-up 116 58† 167 66 <0.001
LVEF, %
Baseline 26 8 25 8 0.293
Follow-up 37 9* 26 8 <0.001
MR grade 1.5 1.0 1.6 1.1 0.400
alues are mean SD or n. p values in bold are statistically significant. *p 0.05, follow-up versus
aseline. †By definition, follow-up versus baseline.
6MWT 6-min walk test; ACE angiotensin-converting enzyme; eGFR estimated glomerular
ltration rate; LVEDV  left ventricular end-diastolic volume; LVEF  left ventricular ejection
raction; LVESV left ventricular end-systolic volume; MRmitral regurgitation; NYHANew York
eart Association; QoL  quality of life.p  0.001 vs. eGFR 60 to 90 ml/min/1.73 m2 and p 
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Renal Function in CRT February 1, 2011:549–55.001 vs. eGFR 90 ml/min/1.73 m2). On the contrary,
urvival was comparable between the eGFR90 ml/min/1.73 m2
nd eGFR 60 to 90 ml/min/1.73 m2 subgroups (p  0.138)
Fig. 2).
Finally, eGFR was tested as an independent predictor for
ortality using a Cox proportional hazards model, adjusting
or age, sex, etiology of heart failure, QRS duration, NYHA
unctional class, use of ACE-inhibitors or AII-blockers, use
f diuretics, LV volumes, LVEF, and MR grade. Estimated
FR remained a very strong predictor of survival after
RT, with a corrected hazard ratio (HR) of 0.97 (95%
onfidence interval [CI]: 0.96 to 0.98, p  0.001) for every
ml/min/1.73 m2 increase in baseline eGFR (Table 3).
hanges in renal function after CRT. In a subset of 133
atients with routinely acquired blood samples at 6-month
atient Characteristics of the 3 eGFR SubgroupsTable 2 Patient Characteristics of the 3 eGFR Subgroups
Variable
eGFR <60 ml/min/1.73 m2
(n  193)
e
Age, yrs 71 8
Sex, M/F 152/41
Ischemic etiology 123 (64%)
QRS duration, ms 161 30
Systolic blood pressure, mm Hg 111 19
Diastolic blood pressure, mm Hg 69 12
ACE inhibitors/AII blockers 169 (88%)
Diuretics 176 (91%)
Beta-blockers 129 (67%)
NYHA functional class 3.1 0.3
6MWT, m 266 99
QoL score 37 16
LVEDV, ml 218 77
LVESV, ml 168 71
LVEF, % 24 8
MR grade 1.7 1.1
alues are mean  SD or n. p values in bold are statistically significant.
Abbreviations as in Table 1.
Figure 1 Differences in Response to CRT
Between the 3 Subgroups
p  0.05 (Bonferroni corrected for 3 comparisons), percentage responders
versus estimated glomerular filtration rate (eGFR) 60 ml/min/1.73 m2. CRT 
cardiac resynchronization therapy.ollow-up, the effect of CRT on evolution of renal function
as assessed. In this subset of patients, a slight deterioration
f renal function at 6-month follow-up was noted (eGFR
1 ml/min/1.73 m2 at baseline vs. eGFR 69 ml/min/1.73 m2
t follow-up, p  0.012). Patients who did not respond to
RT showed deterioration of renal function over the
-month follow-up period (eGFR 4.7 ml/min/1.73 m2
or baseline vs. follow-up, p  0.001), whereas in CRT
esponders, renal function remained stable at 6 months
ollow-up (eGFR 0.6 ml/min/1.73 m2 for baseline vs.
ollow-up, p 0.659). Changes in eGFR between responders
nd nonresponders differed significantly (eGFR 4.7 for
onresponders vs. eGFR 0.6 for responders, p  0.05)
Fig. 3).
iscussion
he findings of the current study can be summarized as
ollows: heart failure patients with moderately or severely
ecreased renal function show lower response to CRT as
ompared with patients with normal or mildly decreased renal
unction. Additionally, patients with severely decreased renal
unction have worse long-term prognosis after CRT. Finally,
atients who demonstrate significant LV reverse remodeling
fter CRT (reduction in LVESV 15% at 6-month follow-
p) have preservation of renal function, whereas patients who
o not exhibit significant LV reverse remodeling have a slight
orsening in renal function after CRT.
Renal failure is highly prevalent among heart failure pa-
ients. It has been estimated that as many as 25% to 50% of
atients with heart failure have impaired renal function (cre-
tinine clearance 60 to 75 ml/min/1.73 m2) (7,20). A
etrospective analysis of the SOLVD (Studies of LV Dysfunc-
ion) trial revealed that in heart failure patients with a LVEF
0–90 ml/min/1.73 m2
(n  204)
eGFR >90 ml/min/1.73 m2
(n  93) p Value
65 8 56 11 <0.001
165/39 75/18 0.856
121 (59%) 49 (53%) 0.200
159 33 147 35 0.001
112 20 115 23 0.387
69 12 70 13 0.868
189 (93%) 88 (95%) 0.084
179 (88%) 69 (74%) <0.001
136 (67%) 73 (78%) 0.088
3.1 0.3 3.0 0.2 0.160
308 105 352 98 <0.001
38 18 33 18 0.091
235 92 229 72 0.127
177 80 170 64 0.423
26 8 27 8 0.022
1.5 1.1 1.1 0.8 <0.001GFR 635%, a total of 32% of patients had an eGFR 60 ml/min/
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February 1, 2011:549–55 Renal Function in CRT.73 m2. The same analysis demonstrated a strong relation
etween renal function and all-cause mortality; a 10 ml/min/
.73 m2 lower eGFR was associated with a 1.064 (95% CI:
.033 to 1.096) higher risk for mortality in these patients (7).
he currently observed hazard ratio for eGFR is fairly higher
han that reported by SOLVD, but may be attributed to the
act that in the SOLVD trial, only 12% of patients were in
YHA functional class III or IV, versus 100% in the present
tudy.
Figure 2 Kaplan-Meier Survival Curves
Shown are survival curves for time to all-cause mortality in patients with an estima
1.73 m2, and an eGFR 60 ml/min/1.73 m2. p  0.001, overall comparison bet
p  0.138, eGFR 90 ml/min/1.73 m2 versus eGFR 60 to 90 ml/min/1.73 m2;
p  0.001, eGFR 90 ml/min/1.73 m2 versus eGFR 60 ml/min/1.73 m2.
Uni- and Multivariable Cox Proportional Hazards MTable 3 Uni- and Multivariable Cox Proportion
Univaria
HR (95% CI)
Age, yrs 1.04 (1.02–1.06)
Male 1.79 (1.02–3.14)
Ischemic HF 1.69 (1.13–2.54)
QRS ms 1.00 (0.99–1.01)
NYHA functional class 2.25 (1.38–3.68)
Diuretics 2.15 (1.05–4.42)
ACE inhibitors/AII blockers 0.75 (0.41–1.36)
eGFR, ml/min/1.73 m2 0.97 (0.96–0.98)
LVESV, ml 1.00 (1.00–1.01)
LVEDV, ml 1.00 (1.00–1.00)
LVEF, % 0.96 (0.94–0.99)
MR grade 1.45 (1.23–1.72)p values in bold are statistically significant.
CI  confidence interval; other abbreviations as in Table 1.Similar observations as in SOLVD were noted in another
arge trial, CHARM (Candesartan in Heart Failure: Assess-
ent of reduction in Mortality and Morbidity) (8). In this
tudy, around 35% of the 2,680 patients had an eGFR 60
l/min/1.73 m2, and this was associated with increased mor-
ality during long-term follow-up (HR: 1.50, 95% CI: 1.15 to
.00). The findings of these large interventional trials in heart
ailure patients demonstrate that renal failure is a major
eterminant of long-term outcome in this population.
omerular filtration rate (eGFR) 90 ml/min/1.73 m2, an eGFR 60 to 90 ml/min/
he 3 groups. The following p values are Bonferroni corrected for 3 comparisons:
.001, eGFR 60 to 90 ml/min/1.73 m2 versus eGFR 60 ml/min/1.73 m2; and
for Time to All-Cause Mortalityzards Models for Time to All-Cause Mortality
Multivariable
p Value HR (95% CI) p Value
<0.001
0.043 2.34 (1.30–4.22) 0.005
0.011
0.939
0.001 1.72 (1.02–2.89) 0.041
0.038
0.342
<0.001 0.97 (0.96–0.98) <0.001
0.034
0.124
0.004 0.98 (0.96–1.01) 0.213
<0.001 1.31 (1.10–1.57) 0.003ted gl
ween t
p  0odelsal Ha
ble
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Renal Function in CRT February 1, 2011:549–55More recently, interactions between renal function and
RT have been described. Fung et al. first reported an
ssociation between impaired renal function and clinical
utcome in patients treated with CRT (6). The authors
ound in a small cohort of 85 patients, that patients without
everse remodeling had a deterioration in renal function
61.9 17 ml/min/1.73 m2 vs. 48.8 13.0 ml/min/1.73 m2)
hereas patients with significant LV reverse remodeling
defined as 10% reduction in LVESV) showed a slight
mprovement in renal function (51.7  20.4 ml/min/1.73 m2
t baseline vs. 54.2  19.1 ml/min/1.73 m2 at 3-month
ollow-up, p  0.001). In addition, patients with a deteri-
ration in renal function during follow-up had a signifi-
antly higher mortality rate than patients with preserved
enal function (HR: 1.96, p  0.01). Surprisingly, patients
ho showed no significant LV reverse remodeling at
-month follow-up had a higher baseline eGFR than
atients who demonstrated 10% reduction in LVESV.
his is to some extent contradictory to the current findings,
here CRT responders (patients who showed15% reduc-
ion in LVESV) had higher baseline eGFR than nonre-
ponders. Perhaps the definition of response or differences
n patient characteristics (overall higher baseline eGFR,
arger baseline volumes in the current study) might be
esponsible for this discrepancy.
Another small study on the evolution of renal function
uring CRT showed similar results. In 33 patients under-
oing CRT, Kimura et al. (21) reported that responders to
RT (patients with 0% increase in LVEF at 3-month
ollow-up) had an improvement in eGFR of 3.0  3.4
l/min/1.73 m2, whereas nonresponders (patients with a
ecrease in LVEF at 3-month follow-up) had a deteriora-
ion in renal function of 11.5  4.3 ml/min/1.73 m2.
Figure 3 Change in eGFR From Baseline to 6-Month Follow-Up,
Responders Versus Nonresponders to CRT
In responders to CRT, renal function remained stable at 6-month follow-up
(eGFR 0.6 ml/min/1.73 m2 for baseline versus follow-up, p  0.659),
whereas in nonresponders, renal function showed a slight deterioration at
6-month follow-up (eGFR 4.7 ml/min/1.73 m2 for baseline versus follow-up,
p  0.001). Changes in eGFR between responders and nonresponders were
significantly different (p  0.05).here were no significant differences in baseline renal uunction between responders and nonresponders. The au-
hors concluded that response to CRT results in preserva-
ion of renal function, wheras nonresponders had (further)
eterioration, a finding similar to that in the present study.
The largest, currently available body of evidence for the
eneficial effects of CRT on renal function comes from a
ubanalysis of the MIRACLE (Multicenter InSync Ran-
omized Clinical Evaluation) study (22). In this trial, 453
atients were randomized to either CRT or control group.
atients were divided into 3 subgroups (eGFR 30 to 60
l/min/1.73 m2, eGFR 60 to 90 ml/min/1.73 m2, and
GFR 90 ml/min/1.73 m2), similar to the currently
onstructed subgroups. In all 3 subgroups, the patients in
he CRT group derived superior benefit to the control group
ith regard to decrease in LV volumes and increase in
VEF. There was however, an interesting difference in LV
everse remodeling at 6-month follow-up between the 3
ubgroups. Patients with an eGFR 90 ml/min/1.73 m2 had
mean reduction in LVESV of 53  10 ml, patients with an
GFR of 60 to90 ml/min/1.73 m2 had a mean reduction in
VESV of 40  7 ml, and finally, patients with an eGFR of
0 to 60 ml/min/1.73 m2 had a reduction of 30  9 ml.
lthough the authors did not test for significance of these
esults, this observation remains interesting and further
trengthens the current observation that impaired baseline
enal function results in less response (reverse remodeling) after
RT. What the exact underlying mechanism is on the ob-
erved higher response in patients with preserved renal func-
ion remains currently unclear. Theoretically, impaired renal
unction could be caused by an increased venous pressure (11),
hich in turn may result in less reverse remodeling after CRT.
onversely, impaired renal function was also associated with
ower LVEF and more severe MR in the present study, which in
urn may have influenced CRT response. However, these as-
umptions cannot be confirmed by the current (or any other
ublished) study.
Perhaps the most important question raised by the present
nd earlier mentioned studies (6,21,22) is through which
echanism CRT improves (or maintains) renal function in
eart failure patients. Since renal function (eGFR) is strongly
nfluenced by renal perfusion (23), one explanation might be
he fact that renal perfusion is improved by a CRT induced
ystemic hemodynamic benefit (5). In turn, this systemic
emodynamic benefit is most likely effectuated by an improve-
ent in LV systolic function and/or reduction in MR (24,25).
lthough this hypothesis cannot be confirmed by the current
esults, the mechanism is supported by recent findings reported
y Mullens et al. (5), obtained with invasive hemodynamic
valuation in CRT recipients. In this study including 40
atients who previously underwent CRT implantation, switch-
ng OFF biventricular pacing resulted in an immediate 7%
ecrease in systemic systolic pressure, as well as a 22% increase
n central venous pressure. Since CRT increases systemic
ystolic pressure and decreases central venous pressure, it is not
nlikely that either of these, or an interplay between the 2, is
r
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February 1, 2011:549–55 Renal Function in CRTesponsible for the observed favorable effect of CRT on eGFR
and prognosis) (5,11).
tudy limitations. Since the current study represents a
onrandomized observational design, we could only assess
he absolute effect of CRT in the different eGFR sub-
roups. The relative effect of CRT (vs. no CRT) may be
imilar among subgroups, as reported by both the subanaly-
is from the MIRACLE trial (22) and CARE-HF
Care-HF Cardiac Resynchronization in Heart Failure) (2).
Also, progression of renal dysfunction as part of the
atural course of disease may have been of influence.
atients with a small reduction in renal function were
lassified as “nonresponders” but (in individual patients)
ay well be “responders,” since progression of disease may
ave been attenuated compared with natural history, and
eterioration of renal function may have been more exten-
ive in the absence of CRT (5,26). The same reasoning may
e applicable to LV reverse remodeling.
onclusions
he current study provides novel insight in the effect of
aseline renal function on reverse remodeling and the
ubsequent long-term prognosis, the effects of remodeling
n changes in renal function, in the largest patient cohort
escribed to date. Although it is known from the important
ubanalysis from MIRACLE that the relative effects of CRT
as compared with controls) on LV volumes and LVEF is
imilar among the 3 renal function subgroups, the current
tudy confirms the suggestion that the absolute effect of CRT
ay be larger in patients with preserved renal function. In
ddition, these patients have a better long-term prognosis than
atients with impaired renal function. The present findings
ay help to further determine which patient will respond after
RT, and which patient might not respond. Even though
atient selection for CRT may not be altered by knowledge of
re-implantation renal function, it may help to place the
ndividual patient in the appropriate part of the response
pectrum and aid in setting of expectations.
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